Last reviewed · How we verify
BI 765128
At a glance
| Generic name | BI 765128 |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Cellulitis
- Blepharitis
- Eye pain
- Iridocyclitis
- Vision blurred
- Vitreous floaters
- Vitreous haemorrhage
- Diarrhoea
- Asthenia
- Infective exacerbation of chronic obstructive airways disease
- Blood pressure increased
- Blood urine present
Key clinical trials
- A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BI 765128 CI brief — competitive landscape report
- BI 765128 updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI